Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)

Launched by MERIT MEDICAL SYSTEMS, INC. · Nov 22, 2023

Keywords

ClinConnect Summary

The BETTER-UAE trial is studying the use of a new type of particles called Bearing nsPVA for a procedure known as uterine artery embolization. This treatment is designed for women who have painful symptoms caused by uterine fibroids, which are non-cancerous growths in the uterus. The trial is actively recruiting women aged 18 and older who have these symptoms and are suitable for the procedure. Participants must also be able to provide consent and cannot be pregnant or have certain pelvic infections or cancers.

If you join this study, you will receive the Bearing nsPVA embolization treatment, and researchers will keep track of your health and the treatment’s effectiveness for up to six months. This is an important step to ensure the safety and performance of the treatment. Your involvement could help improve future options for women dealing with uterine fibroids.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Adult women ≥ 18 years old at the time of enrollment.
• • Subject has symptomatic uterine fibroid(s), suitable to embolization.
• • Subject provides written informed consent.
• Exclusion Criteria:
• • Subject is pregnant.
• • Subject has suspected pelvic inflammatory disease or any other pelvic infection.
• • Subject has any malignancy of the pelvic region, (e.g., endometrial neoplasia).